Thymosin Alpha-1
Thymic polypeptide. Increases T-cell efficiency, stimulates IL-2/IFN-y and improves MHC Class I expression. Strengthens immune surveillance.
- Strengthening the immune system
- Adjuvant in vaccines and viral treatments (Hepatitis/HIV)
- Anti-tumour properties (research)
- Reduction of oxidative stressReinforcement of the immune system
- Reduction of oxidative stress
- Very well tolerated.
- Mild local irritation. Very well tolerated.
- Mild local irritation.
Thymosin Alpha-1 (Tα1) is a 28 amino acid peptide derived from the thymus gland, which acts as a master regulator of the immune system, restoring the balance between the body's defences.
READ MORE
What it is (in plain language)
- It is the 'trainer' of your immune system. If your system is weak (frequent infections), Tα1 helps strengthen it. If your system is attacking your own body (autoimmunity), it helps calm it down. It is essential for the maturation of T cells, the body's elite soldiers against viruses and cancer.
Why do you appear online so much
- It has gained immense fame during the pandemic and in immune longevity protocols. It is widely used to combat chronic fatigue, hepatitis, recurrent viral infections and to 'rejuvenate' the immune system of elderly people.
How it is framed today (pragmatic view)
- 1) Evidence: Approved in over 30 countries for the treatment of infections and cancer. 2) Purpose: Immune modulation and antiviral support. 3) Risk: Extremely safe, being one of the most natural peptides to the human body.
How to use this form
- See the 'Immune Protocols' section to understand how Tα1 can be combined with vaccines to increase efficacy.
- Quick profile (curated by Subject 157)
- Class: Other
- Status: Verified
- Use case: Other
- Route: Injectable
- Tags: Injectable|Immune|Approved
- Half-life: ~2 Hours
- Start: Variable
- Duration: Variable
- Mechanism (high level)
Thymic polypeptide. Increases T-cell efficiency, stimulates IL-2/IFN-y and improves MHC Class I expression. Strengthens immune surveillance.
- Evidence (what the literature covers)
RESEARCH RANGE (Clinical, Non-prescriptive):
Approved (Zadaxin) in doses of 1.6mg SC.
Level of Evidence: A (Approved in several countries).
- Safety and harm-reduction (non-prescriptive)
Risks: Very well tolerated.
Mild local irritation.
Interactions: Unknown.
- References (anchors)
- Romani, L. (2004) - Thymosin alpha 1 restores immune reactivity in sepsis - https://doi.org/10.1182/blood-2003-11-4036 | PubMed:15044253
- Shishkov, I. (2012) - Thymosin alpha 1 in severe sepsis - https://doi.org/10.1186/cc11932 | PubMed:23347514
Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.
EN 
PT 
FR 
ES 
DE 
IT 
PL